Europese Unie - Nederlands - EMA (European Medicines Agency)

novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - immunosuppressiva - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. psoriatica arthritiscosentyx, alleen of in combinatie met methotrexaat (mtx), is geïndiceerd voor de behandeling van actieve artritis psoriatica bij volwassen patiënten wanneer de respons op eerdere disease modifying anti-reumatische drug (dmard) therapie is dat er onvoldoende. axiale spondyloarthritis (axspa)spondylitis ankylopoetica (as, radiografische axiale spondyloarthritis)cosentyx is geïndiceerd voor de behandeling van actieve spondylitis ankylopoetica bij volwassenen die onvoldoende gereageerd op conventionele therapie. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.

Europese Unie - Nederlands - EMA (European Medicines Agency)

janssen-cilag international nv - ustekinumab - psoriasis; arthritis, psoriatic; crohn disease; colitis, ulcerative - immunosuppressiva - de ziekte van crohn diseasestelara is geïndiceerd voor de behandeling van volwassen patiënten met matig tot ernstig actieve ziekte van crohn die een inadequate respons hadden, verloren reactie of intolerant waren voor zowel conventionele therapie of een tnfa-antagonist of medische contra-indicaties voor dergelijke therapieën. colitis colitisstelara is geïndiceerd voor de behandeling van volwassen patiënten met matig tot ernstig actieve colitis ulcerosa die een ontoereikende respons, verloren reactie of intolerant waren voor zowel conventionele therapie of een biologische of medische contra-indicaties voor dergelijke therapieën. plaque psoriasisstelara is geïndiceerd voor de behandeling van matige tot ernstige plaque psoriasis bij volwassenen die niet reageren op, of een contra-indicatie of intolerantie voor andere systemische therapieën waaronder ciclosporine, methotrexaat en psoraleen ultraviolet-a. pediatrische plaque psoriasisstelara is geïndiceerd voor de behandeling van matige tot ernstige plaque psoriasis bij kinderen en adolescente patiënten vanaf de leeftijd van 6 jaar en ouder, die onvoldoende gecontroleerd worden door, of intolerantie voor andere systemische therapieën of phototherapies. psoriatica arthritisstelara, alleen of in combinatie met methotrexaat, is geïndiceerd voor de behandeling van actieve artritis psoriatica bij volwassen patiënten wanneer de respons op eerdere niet-biologische disease-modifying antirheumatic drug (dmard) therapie is dat er onvoldoende.

Europese Unie - Nederlands - EMA (European Medicines Agency)

recordati netherlands b.v. - siltuximab - giant lymph node hyperplasia - immunosuppressiva - sylvant is geïndiceerd voor de behandeling van volwassen patiënten met multicentrische ziekte van castleman (mcd die negatief zijn aan humaan immunodeficiëntievirus (hiv) en humaan herpesvirus-8 (hhv-8) negatief.

Europese Unie - Nederlands - EMA (European Medicines Agency)

regeneron uk limited - rilonacept - cryopyrin-associated periodic syndromes - immunosuppressiva - rilonacept regeneron is geïndiceerd voor de behandeling van cryopyrin-geassocieerde periodieke syndromen (cap) met ernstige symptomen, met inbegrip van familiale koude auto-inflammatoire syndroom (fcas) en het syndroom van muckle-wells (mws), bij volwassenen en kinderen vanaf 12 jaar en oudere.

Europese Unie - Nederlands - EMA (European Medicines Agency)

leo pharma a/s - brodalumab - psoriasis - immunosuppressiva - kyntheum is geïndiceerd voor de behandeling van matige tot ernstige plaque psoriasis bij volwassen patiënten die in aanmerking komen voor systemische therapie.

Europese Unie - Nederlands - EMA (European Medicines Agency)

janssen-cilag international nv - guselkumab - psoriasis - immunosuppressiva - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.

Europese Unie - Nederlands - EMA (European Medicines Agency)

almirall s.a - tildrakizumab - psoriasis - immunosuppressivum, interleukine-remmers, - ilumetri is geïndiceerd voor de behandeling van volwassenen met matige tot ernstige plaque psoriasis die in aanmerking komen voor systemische therapie.

Europese Unie - Nederlands - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - immunosuppressiva - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Europese Unie - Nederlands - EMA (European Medicines Agency)

roche registration gmbh - satralizumab - neuromyelitis optica - immunosuppressiva - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

Europese Unie - Nederlands - EMA (European Medicines Agency)

ucb pharma s.a.   - bimekizumab - psoriasis - immunosuppressiva - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.